Inhaled milrinone: a new alternative in cardiac surgery?
The administration of milrinone through inhalation has been studied in only a few animal and human studies. Compared to the intravenous administration, inhaled milrinone has been shown to reduce pulmonary artery pressure without systemic hypotension. Therefore, this approach could represent an alternative to nitric oxide. This current state of knowledge of intravenous and inhaled milrinone is presented and summarized.
Denault
André Y
AY
Department of Cardiac Anesthesiology, Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada. denault@videotron.ca
Lamarche
Yoan
Y
Couture
Pierre
P
Haddad
Francois
F
Lambert
Jean
J
Tardif
Jean-Claude
JC
Perrault
Louis P
LP
D000280:Administration, Inhalation; D000818:Animals; D023381:Endpoint Determination / Q000379:methods; D006334:Heart Function Tests; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D007275:Injections, Intravenous; D020105:Milrinone / Q000008:administration & dosage* / Q000494:pharmacology; D008991:Monitoring, Physiologic; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology; D013552:Swine; D019616:Thoracic Surgical Procedures / Q000009:adverse effects; D016896:Treatment Outcome
D010726:Phosphodiesterase Inhibitors; D020105:Milrinone